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ABSTRACT
Aims/Introduction: ‘The Standard Diabetes Manual’ has been developed by clinical
researchers from multiple major institutions in Japan, such as the National Center for Global
Health and Medicine, as a comprehensive disease management program, including collabo-
ration between primary care physicians (PCPs) and specialist services. The present study eval-
uated the efficacy of the manual as a quality improvement strategy in diabetes care by PCPs.
Materials and Methods: A total of 42 PCPs in eight domestic districts of the Japan
Medical Association were allocated to either the intervention group or the control group
in a cluster-randomized design. The PCPs in both groups were provided with a copy of
the Diabetes Treatment Guide published by the Japan Diabetes Society, and the PCPs in
the intervention group additionally received a copy of the manual and a 30-min relevant
seminar at the inception of the intervention. The primary end-point was the adherence to
the following performances as quality indicators: evaluation of retinopathy, and urinary
albumin excretion measurements and serum creatinine measurements, as recommended
by the Japan Medical Association.
Results: A total of 416 patients were enrolled by 36 PCPs. During the 1-year follow-up
period, the proportion of PCPs who adhered to recommendation-concordant measure-
ments of urinary albumin excretion was significantly higher in the intervention group than
in the control group (adherence: 17.9% vs 5.3%, P = 0.016). The other parameters were
not statistically different between the two groups.
Conclusions: Implementation of ‘The Standard Diabetes Manual’ potentially leads to
an improved quality of diabetes management by PCPs.
INTRODUCTION
There has been a growing body of evidence-based clinical
guidelines, and the implementation of such guidelines is
expected to improve the quality and outcome of care. To make
these decision aids feasible and practical in daily practice, clini-
cal researchers from multiple major institutions in Japan, such
as the National Center for Global Health and Medicine, desig-
nated as the national diabetes center, have developed ‘The Stan-
dard Diabetes Manual’ (‘The Manual’) as a comprehensive
disease management program for primary care physicians
(PCPs), including collaboration between PCPs and specialist
services, which has been updated twice annually and is freely
available to the public via the Internet1.
Whether clinical practice guidelines or disease management
programs produce changes in actual clinical performanceReceived 11 November 2015; accepted 3 December 2015
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CLINICAL TRIAL
should be evaluated and measured2. However, there have been
no clinical guidelines or disease management programs in
Japan whose efficacy in the real world has been substantiated.
We thus carried out the Study for the Efficacy Assessment of
the Standard Diabetes Manual (SEAS-DM), a cluster-rando-
mized exploratory trial to investigate the efficacy of ‘The Man-




The SEAS-DM was an open cluster-randomized, two-armed,
exploratory trial carried out in major cities in Japan from
September 2012 through March 2014. It was coordinated by
the National Center for Global Health and Medicine in Japan.
Ethical approval of this study was granted by the institutional
review board at the National Center for Global Health and
Medicine. Written informed consent was obtained from all the
registered PCPs. The PCPs informed their participating patients
of the study using posters, providing them with the opportunity
to decline enrolment.
Study sites and participants
The present study was carried out in eight domestic districts of
the Japan Medical Associations, in which more than three
PCPs were able to participate in each district; each PCP was
expected to enroll approximately 10 patients. The inclusion cri-
teria for the participants were those who satisfied all the follow-
ing conditions: type 2 diabetes mellitus, age between 20 and
75 years, and under the care of the registered PCP for more
than 1 year.
Intervention
The PCPs in each district were randomly allocated to either an
intervention or a control group, with each group as a cluster
and each district as a stratum. The PCPs in both groups were
provided with a copy of the Diabetes Treatment Guide, an
excerpt of the evidence-based clinical guideline3 published by
the Japan Diabetes Society. The PCPs in the intervention group
additionally received a copy of ‘The Manual.’ Furthermore, the
intervention group received a 30-min seminar regarding ‘The
Manual’ at the start of the intervention. Updated copies were
disseminated later, when they became available. The PCPs were
not notified of the study end-points at any point during the
study period.
End-points
The primary end-point was the adherence to the following pro-
cess measures, which were used as quality indicators for
microvascular complication screening, during the 1-year study
period: evaluation of retinopathy by an ophthalmologist (once
annually), measurement of urinary albumin excretion (every
6 months) and measurement of serum creatinine level (every
6 months), as recommended by the Japan Medical Association.
The secondary end-points were the glycated hemoglobin
(HbA1c) at the end of the 1-year period and the adherence to
the following recommendation-concordant performances: mea-
surement of HbA1c (every 3 months), blood pressure (every
3 months) and serum lipids (every 3 months).
Clinical research coordinators, who were not aware of the
allocation of the PCPs, visited each clinic every 3 months and
collected the pertinent data by reviewing the medical records.
Statistical analysis
The estimation of adherence has been described elsewhere4.
Per-protocol analyses of the performance were carried out at
the individual PCP level and accounted for the clustering.
The last observation carried forward method was used to
impute the missing HbA1c variables. The differences in cate-
gorical and continuous parameters were evaluated using the
chi-square test and the Student’s t-test, respectively, with
adjustments for the intracluster correlation coefficient (ICC),
which was set at 0.1. Sensitivity analyses were also carried
out for ICC levels of 0.05 and 0.15. A P-value of less than
0.05 was deemed statistically significant. The analyses were
carried out using Stata 12.0 software (StataCorp, College Sta-
tion, TX, USA).
RESULTS
A total of 42 PCPs in eight DMAs were randomly allocated to
the two groups, and a total of 416 patients were recruited by
36 PCPs. The average interval between randomization and
patient registration was 46.7 days in the intervention group and
47.3 days in the control group. During the 1-year follow-up
period, five patients were lost to follow up: the follow-up rate
was 99.8% (Figure 1). The baseline characteristics and the pro-
cess quality over the preceding 1-year were similar between the
intervention and the control groups (Table 1).
Figure 2 shows the relative changes in adherence at the end
of the study period. The adherence to the blood pressure mea-
surements and blood tests remained relatively high, and there
were no significant differences within or between the groups.
In contrast, the adherence to the evaluation of retinopathy and
albuminuria was relatively low. Both indicators tended to
increase in the intervention group, whereas they declined in
the control group. Although the changes within each group
were not statistically significant, the proportion of PCPs who
carried out recommendation-concordant measurements of uri-
nary albumin excretion was significantly higher in the interven-
tion group than in the control group (adherence: 17.9% vs
5.3%, P = 0.016). This difference remained significant in the
sensitivity analysis throughout the whole range of ICC (data
not shown). The other quality parameters were not statistically
different within or between the two groups. As an outcome
variable, the HbA1c value at the end of the study period did
not differ significantly between the intervention and control
groups (mean – standard error: 7.1 – 0.1% vs 7.1 – 0.1%,
P = 0.90).
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DISCUSSION
‘The Manual’ has been developed mainly for PCPs to make the
evidence-based clinical guideline3 more practical and specific,
with the intention of improving quality of care. Evidence-based
comprehensive disease management5, including collaboration
between PCPs and specialist services, has been clinically shown
to improve the quality and outcome of diabetes care in several
other countries6–11. In Japan, however, no studies have been
published regarding quality improvement through the imple-
mentation of clinical practice guidelines or disease management,
and this is the first randomized trial on this topic.
Our findings in the present pragmatic trial suggest a feasible
improvement in daily clinical diabetes care by PCPs by imple-
menting this practice manual. The strength of the present study
was that it had a cluster-randomized design to minimize bias
and contamination. The extremely high follow-up rate also
made it highly valid. Although the allocation was not masked to
the participants, the end-points were not disclosed during the
study period, which helped to minimize information bias. The
findings of the sensitivity analysis based on the ICC were robust.
In addition, the study provided actual facts regarding the current
status of quality of care for diabetes by PCPs in Japan.
A recent meta-analysis showed that disease management pro-
grams significantly increased the likelihood that patients receive
screening for nephropathy (relative risk 1.28) and retinopathy
(relative risk 1.22)7. In the current study, we found a grossly
equivalent improvement in nephropathy monitoring based on
microalbuminuria. The quality improvement strategies also sig-
Enrollment (42 PCPs)
Randomization (42 PCPs)
Intervention group (22 PCPs) Control group (20 PCPs)
Recuritment (15 PCPs/182 patients)Recruitment (21 PCPs/234 patients)
Patients lost to follow up (n = 4)
- Moved out of area (n = 3)
Patients lost to follow up (n = 1)
- Moved out of area (n = 1)
- Consent withdrawal (n = 1)
Analysis (21 PCPs/230 patients) Analysis (15 PCPs/181 patients)
Figure 1 | Trial profile. PCP, primary care physician.
Table 1 | Baseline characteristics of participants
Intervention group Control group P-value*
Physicians (n) 22 20
Patients (n) 234 182
Men (%) 58.3 58.6 0.95
Mean age, years (SD) 62.2 (8.6) 62.4 (9.2) 0.95
Mean HbA1c, % (SD) 7.1 (0.1) 7.0 (0.1) 0.76
Adherence (%)
Retinopathy screening 8.7 7.2 0.44
Urinary albumin measurement 17.2 6.9 0.05
Serum creatinine measurement 82.4 78.7 0.56
HbA1c measurement 88.6 86.7 0.62
Lipids measurement 67.5 63.3 0.43
Blood pressure measurement 95.5 94.5 0.24
*Adjusted for intracluster correlation coefficient. HbA1c, glycated hemoglobin; SD, standard deviation.
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nificantly decreased the overall HbA1c level by 0.37%, but their
effectiveness varied depending on the baseline HbA1c control:
the change was non-significant for those whose baseline HbA1c
level was less than 8.0%7. There was no significant difference in
the achieved HbA1c between the two groups in our trial, partly
because of good glucose control. Although speculative, the lower
adherence ratios in the measures of HbA1c, blood pressure and
serum lipids observed in the intervention group might have
reflected fewer clinic visits secondary to the improved outcomes
for these factors.
Of note, although the adherence to blood pressure measure-
ments and blood test-related measures was relatively high, the
adherence to blood test-unrelated screenings for microvascular
complications was lower in Japan than in other countries7. This
fact points to the gap between ideal and actual care for patients
with diabetes: despite high-quality evidence showing improved
clinical outcomes for patients with diabetes who receive various
preventive and therapeutic interventions, many diabetic patients
do not receive them in practical settings. The dissemination of
‘The Manual’ could potentially lead to an improvement in the
quality of diabetes-related vascular risk factor management in
the real world.
Several limitations of our investigation should be noted. The
present study was an exploratory pilot trial with a short follow-
up period, and the sample size was not prespecified. An investi-
gation of the clinical outcomes would likely be premature, but
process evaluation, rather than outcome measurement, is likely
to be the best and fastest indicator of quality assurance10,12, and
the results would support validations of the efficacy of this
manual. In light of the moderately long time-lag between ran-
domization and patient registration, the baseline adherence
might have been affected, because performance changes during
this interval were accounted for in the pre-intervention adher-
ence. However, the interval time and the baseline process mea-
sures were similar in both groups, and were unlikely to have
caused bias in the final analysis. The lack of data regarding
complications, lipid levels and blood pressure values might limit
the external validity of this study.
Despite these limitations, our trial can provide clinicians with
information regarding the potential quality improvement
afforded by this disease management program, which might
encourage more physician involvement in guideline develop-
ment, and help to align clinical and economic incentives5, as
positive consequences of behavior encourage the adoption of
specific behaviors8.
In conclusion, our analysis of the quality indicators in this
investigation suggests that ‘The Manual’ leads to an improved
quality of diabetes management by PCPs. Larger trials are war-
ranted to ascertain the potential long-term impact on glucose
control, the risk of diabetic complications and mortality.
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Figure 2 | Adherence ratio for each performance. Relative changes in adherence (boxes) with the 95% confidence intervals (lines) are shown. Filled
boxes and solid lines, intervention group; open boxes and dotted lines, control group. *The chi-square test, adjusted for intracluster correlation
coefficient. HbA1c, glycated hemoglobin; NS, not significant.
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